• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

马查多-约瑟夫病患者共济失调的进展

Progression of ataxia in patients with Machado-Joseph disease.

作者信息

França Marcondes C, D'Abreu Anelyssa, Nucci Anamarli, Cendes Fernando, Lopes-Cendes Iscia

机构信息

Department of Neurology, University of Campinas, São Paulo, Brazil.

出版信息

Mov Disord. 2009 Jul 15;24(9):1387-90. doi: 10.1002/mds.22627.

DOI:10.1002/mds.22627
PMID:19441132
Abstract

Although ataxia is the most distressing manifestation of Machado-Joseph disease (MJD), little is known about its natural history. Therefore, we prospectively followed a cohort of patients with MJD for 13 months to characterize the progression of ataxia and identify its contributory factors. The international cooperative ataxia rating scale (ICARS) was used to estimate severity of ataxia at baseline and at follow-up. Thirty-four patients were enrolled in the study, 22 of whom were men. Mean age at onset of the disease was 34.7 years and length of expanded CAG repeat was 66. Mean ICARS scores at baseline was 37.6 and at follow-up was 42.7 (P < 0.001). Multivariate analysis did not find significant association of progression of disease and age at disease onset, length of expanded (CAG), or duration of disease.

摘要

尽管共济失调是马查多-约瑟夫病(MJD)最令人苦恼的表现,但对其自然病史却知之甚少。因此,我们对一组MJD患者进行了为期13个月的前瞻性随访,以描述共济失调的进展情况并确定其促成因素。采用国际合作共济失调评定量表(ICARS)在基线和随访时评估共济失调的严重程度。34例患者纳入本研究,其中22例为男性。疾病发病的平均年龄为34.7岁,CAG重复序列扩展长度为66。基线时ICARS平均评分为37.6,随访时为42.7(P<0.001)。多变量分析未发现疾病进展与疾病发病年龄、CAG重复序列扩展长度或疾病持续时间之间存在显著关联。

相似文献

1
Progression of ataxia in patients with Machado-Joseph disease.马查多-约瑟夫病患者共济失调的进展
Mov Disord. 2009 Jul 15;24(9):1387-90. doi: 10.1002/mds.22627.
2
Muscle excitability abnormalities in Machado-Joseph disease.马查多-约瑟夫病中的肌肉兴奋性异常。
Arch Neurol. 2008 Apr;65(4):525-9. doi: 10.1001/archneur.65.4.525.
3
Cognitive impairments in Machado-Joseph disease.马查多-约瑟夫病中的认知障碍。
Arch Neurol. 2004 Nov;61(11):1757-60. doi: 10.1001/archneur.61.11.1757.
4
The international cooperative ataxia rating scale in Machado-Joseph disease. Comparison with the unified multiple system atrophy rating scale.马查多-约瑟夫病的国际合作共济失调评定量表。与统一多系统萎缩评定量表的比较。
Mov Disord. 2007 Oct 15;22(13):1976-9. doi: 10.1002/mds.21735.
5
Related factors of ICARS and SARA scores on spinocerebellar ataxia type 3/Machado-Joseph disease.3型脊髓小脑共济失调/马查多-约瑟夫病中ICARS和SARA评分的相关因素
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Jun;36(6):498-503. doi: 10.3969/j.issn.1672-7347.2011.06.005.
6
Chronic pain in Machado-Joseph disease: a frequent and disabling symptom.马查多-约瑟夫病中的慢性疼痛:一种常见且致残的症状。
Arch Neurol. 2007 Dec;64(12):1767-70. doi: 10.1001/archneur.64.12.1767.
7
Non-movement disorder heralds symptoms of Machado-Joseph disease years before ataxia.在共济失调出现数年之前,非运动障碍就预示着马查多-约瑟夫病的症状。
Mov Disord. 2005 Jun;20(6):739-41. doi: 10.1002/mds.20419.
8
Prospective study of peripheral neuropathy in Machado-Joseph disease.马查多-约瑟夫病周围神经病变的前瞻性研究。
Muscle Nerve. 2009 Dec;40(6):1012-8. doi: 10.1002/mus.21396.
9
Serum concentrations of NSE and S100B in spinocerebellar ataxia type 3/Machado-Joseph disease.3型脊髓小脑共济失调/马查多-约瑟夫病患者血清中神经元特异性烯醇化酶(NSE)和S100B蛋白的浓度
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Jun;36(6):504-10. doi: 10.3969/j.issn.1672-7347.2011.06.006.
10
Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.104例弗里德赖希共济失调患者长期随访中的神经、心脏和动眼神经进展情况。
Arch Neurol. 2007 Apr;64(4):558-64. doi: 10.1001/archneur.64.4.558.

引用本文的文献

1
Machado-Joseph disease in Brazil and other South American countries: A systematic Review and Meta-analysis of Prevalence, CAG Repeat Lengths, Age At Onset, and Ancestry.巴西及其他南美国家的马查多-约瑟夫病:患病率、CAG重复长度、发病年龄及祖先的系统评价与荟萃分析
Cerebellum. 2025 Jun 4;24(4):108. doi: 10.1007/s12311-025-01854-7.
2
Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset.脊髓小脑共济失调 1、2、3 和 6 型在共济失调发作前后的疾病进展。
Ann Clin Transl Neurol. 2023 Oct;10(10):1833-1843. doi: 10.1002/acn3.51875. Epub 2023 Aug 17.
3
The Natural History of Spinocerebellar Ataxia Type 3 in Mainland China: A 2-Year Cohort Study.
中国大陆3型脊髓小脑共济失调的自然史:一项为期2年的队列研究。
Front Aging Neurosci. 2022 Jul 5;14:917126. doi: 10.3389/fnagi.2022.917126. eCollection 2022.
4
The progression rate of spinocerebellar ataxia type 3 varies with disease stage.脊髓小脑性共济失调 3 型的进展速度因疾病阶段而异。
J Transl Med. 2022 May 14;20(1):226. doi: 10.1186/s12967-022-03428-1.
5
Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.多聚谷氨酰胺(PolyQ)疾病中的修饰途径:从遗传筛选到药物靶点。
Cell Mol Life Sci. 2022 May 3;79(5):274. doi: 10.1007/s00018-022-04280-8.
6
Quantitative evaluation of upper limb ataxia in spinocerebellar ataxias.定量评估脊髓小脑共济失调的上肢共济失调。
Ann Clin Transl Neurol. 2022 Apr;9(4):529-539. doi: 10.1002/acn3.51528. Epub 2022 Mar 15.
7
Evolution of disability in spinocerebellar ataxias type 1, 2, 3, and 6.脊髓小脑性共济失调 1、2、3、6 型的残疾演变。
Ann Clin Transl Neurol. 2022 Mar;9(3):286-295. doi: 10.1002/acn3.51515. Epub 2022 Feb 21.
8
Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.CAG 重复型脊髓小脑共济失调的评定量表和生物标志物:对治疗开发的影响。
J Neurol Sci. 2021 May 15;424:117417. doi: 10.1016/j.jns.2021.117417. Epub 2021 Apr 1.
9
Gender Differences in Non-sex Linked Disorders: Insights From Huntington's Disease.非性连锁疾病中的性别差异:来自亨廷顿舞蹈症的见解
Front Neurol. 2020 Jul 7;11:571. doi: 10.3389/fneur.2020.00571. eCollection 2020.
10
State biomarkers for Machado Joseph disease: Validation, feasibility and responsiveness to change.马查多-约瑟夫病的状态生物标志物:验证、可行性及对变化的反应性
Genet Mol Biol. 2019;42(1 suppl 1):238-251. doi: 10.1590/1678-4685-GMB-2018-0103. Epub 2019 Jun 10.